2006/11/17 - Application for industrial reserve for national defense 2007, result published via internet
Unit Briefing
Ever since her establishment in 2000, Microbio has devoted rigorously in symbiotic fermentation in TCM biotransformation technology platform and manufacturing process. MS-20, the first product based on soybean was developed as botanical drug. MS-20 not only approved by DOH for phase III clinical study for decrease neutropenic fever and increase NK cell activity and recruit over 3/4 of patient, but also filed FDA HIND application for phase II study in October 2006, aim for increase survival rate and treatment efficacy of patient with hepatoma. MS-20 Complex will submit FDA for HIND in colorectal cancer. Moreover, Microbio intended to use biotransformation platform to build up huge database for complex compound for further screening. Currently, Microbio is working closely with many research institutions through different Pharmacokinetic studies to search for new active ingredient, and our initial result seems to be promising.
For new drug discovery, it is time consuming as well as require huge money support; in order for Microbio to asset with enough money, development of healthy food product of symbiotic soybean fermentation is also undertaking: Young, it is DOH inspected and Health Food Certified ( with function to improve intestinal flora, improve immunity, and to lower LDL), and marketing to both local and oversea market. Microbio also acquired exclusive right in sales for Great China region from US company Albion Advanced Nutrition for her outstanding technology in mineral amino chelate manufacturing with greater bioavailability and better susceptibility. In addition, Microbio apply TCM raw material follow traditional method with modern extract method adding to chelate amino acid to develop Lee Herb healthy food product line.
Microbio's herbal new drug candidate, functional food, healthy food and chemical database can apply to all kinds of business models in self contained, collaboration and synergistic collaboration all to fortified management strength, and create company value. Facing a brand new 21st century, Microbio takes up responsibility in respect and caring for life, with never ending innovative R&D and manufacturing process to improve quality of human life, promote human health, and by using the newest bio-technology to develop new product series, new botanical drug to meet top grade biotech industry standard.
Development momentum and efficacy in practical
Botanical new drug MS-20 developed by Microbio is proving clinically effective in numbers of therapeutic index, include: decrease neutropenic fever induced by neutrophil in cancer patient, increase NK cell activity in cytotoxic effect toward tumor cells, sooth patient's fatigue and increase appetite. MS-20 is proving to diminish side effect from radio-chemotherapy, as well as an adjuvant for cancer therapy. Besides, MS-20 is undergoing phase III study in Veteran hospital and Shin-Kuan Hospita, and file FDA's IND submission for improving quality of life in Hepatoma patient of final stage, and hoping to increase life span of cancer patient.
Due to the fact that Traditional Chinese medicine raw material selection process cannot be standardized, and also patent protection policy is vague, many of the major pharma player keep away from devotion into botanical new drug discovery. Microbio as the leading precursor in botanical drug developing resulted from R&D, manufacturing process follows strict Western medicine developing model to carry on with quality product, this has open up a door to developing TCM manufacturing in modernization, globalization, and filing global patent to engage with global market
